Global News and Digital Insights
for the Healthcare Industry

Oral drug successful in killing tumours in 80% of patients

A study conducted at the University of Michigan showed that Zanubrutinib, an oral drug, has been seen to shrink lymphoma cancer, one of the most common cancers, in 80% of the patients. 20 patients with slow-growing cancer, called marginal zone lymphoma, saw an 80% of reduction in the cancer cells after the intake of the drug Zanubrutinib. After this research, Zanubrutinib has been approved by the Food and Drug Administration to be used on a contingent basis for adults suffering from marginal zone lymphoma. However, researchers are looking for more effective and tolerable treatments.

Read More from SciTechDaily

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn